Previous 10 | Next 10 |
The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Lumos Pharma, Inc. 2022 Q2 - Results - Earnings Call Presentation
Lumos Pharma press release ( NASDAQ: LUMO ): Q2 GAAP EPS of -$0.94 beats by $0.04 . Revenue of $0.4M (+3900.0% Y/Y) beats by $0.38M . For further details see: Lumos Pharma GAAP EPS of -$0.94 beats by $0.04, revenue of $0.4M beats by $0.38M
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Patients Anticipated from OraGrowtH212 Trial -- -- Cash Runway into Second ...
Lumos Pharma ( NASDAQ: LUMO ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close. The consensus EPS Estimate is -$0.99 and the consensus Revenue Estimate is $0.02M (+100.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 u...
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. The company will host a conference call ...
The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Lumos Pharma, Inc. 2022 Q1 - Results - Earnings Call Presentation
Lumos Pharma, Inc. (LUMO) Q1 2022 Earnings Conference Call May 10, 2022, 16:30 ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Lori Lawley - CFO & Princ...
Lumos Pharma press release (NASDAQ:LUMO): Q1 GAAP EPS of -$0.92 misses by $0.02. Revenue of $0.11M. Cash and equivalents totaling $86.8 million compared to $94.8 million on December 31, 2021. The Company expects an average cash use of approximately $8.5 to $9.5 million per quarter through 202...
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold-- --Clinical Collaboration In...
AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Mass...
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company w...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...